Back to discover
Disease

Acanthamoeba Keratitis

Late-stage therapeutic developmentEmerging research
MeSHAcanthamoeba Keratitis
1
Publications
6
Clinical trials
2021
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2029.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Parasitic Ulcer Treatment Trial
Results expected Q3 20292026-05-01
Major trial resultsImportant
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Results posted2026-01-30
Clinical Milestones2View
Results posted 1
Results expected 1
Activity timeline2

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Polihexanideapproved

Approval — Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children… (2024)

Clinical trials

4 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
6
All trials
1
Active
3
Late-stage
5
Completed
Recruiting

Parasitic Ulcer Treatment Trial

Phase 3 · Recruiting · Jeremy Keenan, MD, MPH
Recently completed

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

Phase 3 · Completed · University of California, San Francisco

Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures - a Pilot Study

N/A · Completed · Medical University of Vienna

Parasitic Ulcer Treatment Trial Pilot

Phase 2 · Completed · University of California, San Francisco

Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis

Phase 3 · Completed · SIFI SpA

Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects

Phase 1 · Completed · SIFI SpA

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaApproval — Polihexanide· Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children from 12 years of age. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes2
  • Acanthamoeba Keratitis1
  • Anti-Bacterial Agents1
Leading journals1
  • Eye (London, England)1
Leading researchers5
  • Deshmukh R1
  • Dua HS1
  • Ho CS1
  • Said DG1
  • Ting DSJ1
Affiliations (unnormalised)2
  • Division of Clinical Neuroscience1
  • Queen's Medical Centre1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Infection of the cornea by an ameboid protozoan which may cause corneal ulceration leading to blindness.

Identifiers
MeSHAcanthamoeba Keratitis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.